Fig. 3

Knockdown NAV2 inhibited migration and invasion of CRC cells in vitro and vivo. a Inhibition of NAV2 expression level in HCT-116/ LoVo cells were testified by qRT-PCR (One-way analysis, both P < 0.0001) and Western blotting. Experiments have been repeated three times b Wound-healing assay for NAV2 shRNA HCT-116 (Student’s t-test, *P = 0.0002) and shRNA LoVo (Student’s t-test, **P < 0.0001) compared with empty vector cells. Photographs were taken at 36 h post wounding. Dashed lines indicated the original wound boundaries. Experiments have been repeated three times. c Cell invasion assays, results were presented as the ratios of migrated NAV2 shRNA cells relative to those of empty vector cells HCT-116 (Student’s t-test, *P < 0.0001) and LoVo (Student’s t-test, **P = 0.0003). Data were representative of three experiments .Original magnification, ×100. d Representative liver metastatic tumors were shown between shRNA cells and empty vector cells; Quantification of the liver macrometastases and micrometastases: shRNA HCT-116 and empty vector cells (Student’s t-test, ***P = 0.0003 *P = 0.0006); shRNA LoVo and empty vector cells (Student’s t-test, ****P = 0.0023,**P = 0.0008); The average tumor volume of shRNA and the empty vector cells: HCT-116, (Student’s t-test, *P = 0.0012); LoVo, (Student’s t-test, **P = 0.0004); The extent of silencing by shRNA in vivo was verified by Western blotting (bottom right)